Next Article in Journal
The Saccharomyces boulardii CNCM I-745 Strain Shows Protective Effects against the B. anthracis LT Toxin
Next Article in Special Issue
Current Status and Future Directions of Botulinum Neurotoxins for Targeting Pain Processing
Previous Article in Journal
Editorial on the Special Issue “Harmful Algal Blooms (HABs) and Public Health: Progress and Current Challenges”
Previous Article in Special Issue
The Inhibitory Effect of Botulinum Toxin Type A on Rat Pyloric Smooth Muscle Contractile Response to Substance P In Vitro
Article Menu

Export Article

Open AccessArticle
Toxins 2015, 7(11), 4442-4454;

Acupoint Injection of Onabotulinumtoxin A for Migraines

Department of Neuroscience, Anatomy, Histology and Embryology, Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, 199 Donggang Xi Road, Lanzhou 730000, China
Department of Anatomy, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, China
Department of Human Anatomy, School of Medicine, Hunan Normal University, 371 Tongzipo Road, Changsha 410013, China
Department of Neurology and Pain Treatment, Gansu Province People Hospital, Lanzhou 730000, China
Author to whom correspondence should be addressed.
Academic Editor: Bahman Jabbari
Received: 25 July 2015 / Revised: 20 October 2015 / Accepted: 20 October 2015 / Published: 30 October 2015
(This article belongs to the Collection Botulinum Toxins on Human Pain)
Full-Text   |   PDF [645 KB, uploaded 30 October 2015]   |  


Onabotulinumtoxin A (BoNTA) has been reported to be effective in the therapy for migraines. Acupuncture has been used worldwide for the treatment of migraine attacks. Injection of a small amount of drug at acupuncture points is an innovation as compared to traditional acupuncture. The purpose of this study was to evaluate and compare the effectiveness of fixed (muscle)-site and acupoint-site injections of BoNTA for migraine therapy in a randomized, double-blinded, placebo-controlled clinical trial extending over four months. Subjects with both episodic and chronic migraines respectively received a placebo (n = 19) or BoNTA (2.5 U each site, 25 U per subject) injection at fixed-sites (n = 41) including occipitofrontalis, corrugator supercilii, temporalis and trapeziue, or at acupoint-sites (n = 42) including Yintang (EX-HN3), Taiyang (EX-HN5), Baihui (GV20), Shuaigu (GB8), Fengchi (GB20) and Tianzhu (BL10). The variations between baseline and BoNTA post-injection for four months were calculated monthly as outcome measures. BoNTA injections at fixed-sites and acupoint-sites significantly reduced the migraine attack frequency, intensity, duration and associated symptoms for four months compared with placebo (p < 0.01). The efficacy of BoNTA for migraines in the acupoint-site group (93% improvement) was more significant than that in the fixed-site group (85% improvement) (p < 0.01). BoNTA administration for migraines is effective, and at acupoint-sites shows more efficacy than at fixed-sites. Further blinded studies are necessary to establish the efficacy of a low dose toxin (25 U) introduced with this methodology in chronic and episodic migraines. View Full-Text
Keywords: botulinum toxin type A; migraine; fixed-sites injection; acupoint-sites injection; randomized and placebo-controlled trial botulinum toxin type A; migraine; fixed-sites injection; acupoint-sites injection; randomized and placebo-controlled trial

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Hou, M.; Xie, J.-F.; Kong, X.-P.; Zhang, Y.; Shao, Y.-F.; Wang, C.; Ren, W.-T.; Cui, G.-F.; Xin, L.; Hou, Y.-P. Acupoint Injection of Onabotulinumtoxin A for Migraines. Toxins 2015, 7, 4442-4454.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top